Mentice is evolving from a niche endovascular “flight simulator” leader into a clinical-performance platform that embeds simulation and patient-specific planning into the angio-suite—while restructuring unlocks operating leverage.
Overview
Mentice AB is a long-established leader in simulation for image-guided interventional therapies, benefiting from demographic tailwinds (aging populations, rising cardiovascular/neurovascular disease) and a global shift toward competency-based training for minimally invasive procedures. The company has built a defensible technology stack anchored by the VIST haptic simulator platform and is expanding from pure training into clinical performance via two strategic capability adds: Ankyras decision support (enabling patient-specific “digital twin” planning + rehearsal) and Biomodex physical simulation assets (hybrid models with realistic tissue compliance and flow). Commercially, OEM integration—most notably with Siemens Healthineers—embeds simulation into real angio-suite controls and supports adoption of robotic-assisted interventions, particularly in China. Financially, 2024 was transitional (sales up but order intake down early), while 2025 delivered a clear profitability inflection after restructuring (record Q4 EBITDA), although FX headwinds muted reported growth. The investment debate centers on whether sustained post-restructuring margins and workflow expansion will close the apparent valuation gap versus peers.